Tokyo, July 8 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058388) titled 'Effectiveness of guselkumab on ulcerative colitis patients with a history of ustekinumab loss of response' on July 7.
Study Type:
Observational
Primary Sponsor:
Institute - Janssen Pharmaceutical K.K.
Condition:
Condition - Ulcerative colitis
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - The primary objective of this study is to evaluate the efficacy of GUS in UC patients with a history of UST loss of response (LoR).
Basic objectives2 - Efficacy
Eligibility:
Age-lower limit - 15
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion...